Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.

CD24 biomarker cetuximab colorectal cancer single nucleotide polymorphism

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Oct 2020
Historique:
received: 16 08 2020
revised: 03 10 2020
accepted: 06 10 2020
entrez: 17 10 2020
pubmed: 18 10 2020
medline: 18 10 2020
Statut: epublish

Résumé

Cetuximab, an IgG1 EGFR-directed antibody, promotes antibody-dependent cell-mediated cytotoxicity. We hypothesized that single-nucleotide polymorphisms (SNPs) in immune regulatory pathways may predict outcomes in patients with metastatic colorectal cancer treated with cetuximab-based regimens. A total of 924 patients were included: 105 received cetuximab in IMCL-0144 and cetuximab/irinotecan in GONO-ASL608LIOM01 (training cohort), 225 FOLFIRI/cetuximab in FIRE-3 (validation cohort 1), 74 oxaliplatin/cetuximab regimens in JACCRO CC-05/06 (validation cohort 2), and 520 FOLFIRI/bevacizumab in FIRE-3 and TRIBE (control cohorts). Twelve SNPs in five genes (

Identifiants

pubmed: 33065994
pii: cancers12102947
doi: 10.3390/cancers12102947
pmc: PMC7601940
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30CA014089-27S1
Pays : United States
Organisme : Dhont Family Foundation
ID : -
Organisme : Wunderglo Foundation
ID : -
Organisme : Daniel Butler Research Fund
ID : -
Organisme : German Cancer Aid (Mildred-Scheel Foundation)
ID : -

Références

PLoS One. 2014 Dec 26;9(12):e115848
pubmed: 25541686
Br J Clin Pharmacol. 2012 May;73(5):776-85
pubmed: 22486600
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32
pubmed: 18765800
Int J Biol Markers. 2014 Mar 24;29(1):e49-54
pubmed: 24474454
Oncol Lett. 2016 Sep;12(3):1868-1876
pubmed: 27602116
Cancer Immunol Res. 2016 Apr;4(4):366-74
pubmed: 26817995
Eur J Cancer. 2012 Aug;48(12):1774-80
pubmed: 22305465
J Clin Oncol. 2007 Aug 20;25(24):3712-8
pubmed: 17704420
Mol Ther. 2013 Jan;21(1):91-100
pubmed: 22990672
Inflamm Bowel Dis. 2010 May;16(5):795-803
pubmed: 19998456
Nat Med. 2016 Jun;22(6):624-31
pubmed: 27135741
Stem Cells. 2013 Sep;31(9):2024-30
pubmed: 23553902
Clin Cancer Res. 2008 Dec 1;14(23):7884-95
pubmed: 19047118
J Clin Oncol. 2009 Mar 1;27(7):1122-9
pubmed: 19164213
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
Cell Death Dis. 2014 Mar 27;5:e1149
pubmed: 24675467
Gut. 2001 Feb;48(2):176-85
pubmed: 11156637
Clin Immunol. 2004 Oct;113(1):47-55
pubmed: 15380529
Nucleic Acids Res. 2008 Jan;36(Database issue):D820-4
pubmed: 17986460
Clin Cancer Res. 2007 Mar 1;13(5):1552-61
pubmed: 17332301
Gut. 2015 Feb;64(2):353-4
pubmed: 23704317
Cancer Sci. 2017 Mar;108(3):455-460
pubmed: 28075526
J Clin Invest. 2007 Sep;117(9):2570-82
pubmed: 17710230
World J Gastroenterol. 2015 May 21;21(19):6052-9
pubmed: 26019472
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W600-5
pubmed: 19417063
Cytogenet Cell Genet. 1995;70(1-2):119-25
pubmed: 7736776
Pharmacogenomics J. 2015 Dec;15(6):521-9
pubmed: 25752522
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):473-8
pubmed: 17197414
J Exp Med. 2004 Oct 18;200(8):1083-9
pubmed: 15477346
World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30
pubmed: 26909137
Clin Cancer Res. 2006 Feb 15;12(4):1144-51
pubmed: 16489067
Gastroenterology. 2013 Aug;145(2):416-25.e1-4
pubmed: 23669411
J Clin Oncol. 2006 Oct 20;24(30):4914-21
pubmed: 17050875
Cell Physiol Biochem. 2017;44(3):1038-1050
pubmed: 29179214
Clin Cancer Res. 2013 Mar 1;19(5):1126-38
pubmed: 23209031
Cancer Res. 2010 Jul 15;70(14):5942-52
pubmed: 20634405
Br J Cancer. 2012 Jan 3;106(1):141-7
pubmed: 22108515
Oncogene. 2013 Jun 6;32(23):2873-81
pubmed: 22797062
Breast Cancer Res Treat. 2013 Feb;137(3):927-37
pubmed: 23314606
Nature. 2011 Jan 20;469(7330):415-8
pubmed: 21113151
Pharmacogenomics J. 2014 Apr;14(2):142-50
pubmed: 23817222
Nat Rev Microbiol. 2011 May;9(5):356-68
pubmed: 21423246
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8
pubmed: 18952840
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Eur J Cancer. 2010 Jun;46(9):1703-11
pubmed: 20399639
Cancer Sci. 2007 Aug;98(8):1275-80
pubmed: 17498200
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Breast Cancer Res Treat. 2012 Apr;132(3):819-31
pubmed: 21960110
Cancer Sci. 2010 May;101(5):1080-8
pubmed: 20331636
Int J Cancer. 2014 May 1;134(9):2146-55
pubmed: 24136682
Tumour Biol. 2014 Sep;35(9):8927-32
pubmed: 24894672
Cancer Treat Rev. 2018 Feb;63:48-60
pubmed: 29223828
Mol Cancer Ther. 2012 Aug;11(8):1829-37
pubmed: 22675042

Auteurs

Nico B Volz (NB)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Diana L Hanna (DL)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Sebastian Stintzing (S)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Department of Medicine III, University Hospital LMU Munich, 80539 Munich, Germany.

Wu Zhang (W)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Dongyun Yang (D)

Department of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Shu Cao (S)

Department of Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Yan Ning (Y)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Satoshi Matsusaka (S)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Yu Sunakawa (Y)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Martin D Berger (MD)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Chiara Cremolini (C)

U.O. Oncologia Medica 2-Aziendo Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.

Fotios Loupakis (F)

U.O. Oncologia Medica 2-Aziendo Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.

Alfredo Falcone (A)

U.O. Oncologia Medica 2-Aziendo Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.

Heinz-Josef Lenz (HJ)

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.

Classifications MeSH